News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Curis, Inc. Reports Second Quarter 2009 Financial Results and Provides Pipeline Update
July 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today reported its financial results for the second quarter ended June 30, 2009.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Curis, Inc.
MORE ON THIS TOPIC
Gene therapy
Lilly Doubles Down on Eye Diseases, Adding to BD Spree
November 10, 2025
·
1 min read
·
Annalee Armstrong
Metabolic disorders
Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases
November 10, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Pfizer’s Winning Bid for Metsera Concludes ‘Real Housewives of Biopharma’
November 10, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Pfizer Wins Metsera Bidding War Over Novo With Final $10B Price Tag
November 7, 2025
·
1 min read
·
Dan Samorodnitsky